Bayer Bets $1.3B On Kumquat Cancer Drug Candidate
By Jade Martinez-Pogue · August 12, 2025, 6:16 PM EDT
Pharmaceutical company Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, on Tuesday announced that they have entered into an exclusive global license and collaboration agreement under which Kumquat will receive...
To view the full article, register now.